Presenter:
Nancy Ann Oberheim Bush, MD. PhD, UCSF
2025 SNO/ASCO Conference Independent Symposium
Friday, August 15, 2025
In this session, Dr. Nancy Ann Oberheim Bush presents clinical validation and real world patient cases for CSF liquid biopsies in CNS tumors. The focus is on tumor-derived DNA in CSF and the role in diagnosis, classification, disease monitoring, treatment selection and clinical management.
Learning Objectives:
- Participants will gain an understanding of how next generation sequencing in CSF can be used to detect gene level variants and chromosome arm level alterations from tumor derived DNA to inform the diagnosis and management of CNS malignancies.
- Actual patient case studies will be presented that demonstrate how investigation of tumor-derived DNA in CSF using Belay Summit™ can help the clinician formulate treatment approaches for patients with primary and secondary CNS tumors.
- Participants will leave with technical knowledge of the clinical validity of Belay Summit™ across metastatic brain cancers, gliomas, GBMs, medulloblastomas, and astrocytomas.
- Participants will learn about Belay’s Vantage™ test that can evaluate MGMT promoter methylation in CSF with high accuracy. As MGMT promoter methylation testing is recommended in all high-grade gliomas and MGMT status can change, this is significant development to help these patients.
